SCHEMBL990057

SCHEMBL990057

CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)ncn3C)cc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.67
ERBB2 P04626 4/20 0.63
MAPK8 P45983 4/20 0.63
MAPK9 P45984 4/20 0.63
CSNK1D P48730 4/20 0.63
DYRK1A Q13627 4/20 0.63
PRKD2 Q9BZL6 4/20 0.63
PRKD3 O94806 3/20 0.63
MAP4K4 O95819 3/20 0.63
MAP4K2 Q12851 3/20 0.63
CAMK2B Q13554 3/20 0.63
ERBB4 Q15303 3/20 0.63
MINK1 Q8N4C8 3/20 0.63
PIM1 P11309 3/20 0.63
FGFR1 P11362 3/20 0.63
LIMK1 P53667 3/20 0.63
CAMK2G Q13555 2/20 0.63
PIM3 Q86V86 2/20 0.63
MKNK2 Q9HBH9 2/20 0.63
TAOK1 Q7L7X3 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL990878 0.93 MAPK14 (0.68) MAPK14ERBB2MAPK8MAPK9CSNK1D
SCHEMBL990654 0.91 MAPK14 (0.55) MAPK14ERBB2MAPK8MAPK9CSNK1D
SCHEMBL989496 0.84 MAPK14 (0.57) MAPK14ERBB2MAPK8MAPK9CSNK1D
SCHEMBL5770065 0.80 MAPK14 (1.00) MAPK14ERBB2MAPK8MAPK9CSNK1D
SCHEMBL13143881 0.77 MAPK8 (1.00) MAPK14ERBB2MAPK8MAPK9CSNK1D
SCHEMBL990938 0.77 CSNK1D (0.61) MAPK14ERBB2MAPK8MAPK9CSNK1D
SCHEMBL29676815 0.76 MAPK14 (0.61) MAPK14DYRK1ATNIKNR3C2KDM2B
SCHEMBL18041561 0.76 MAPK14 (0.61) MAPK14DYRK1ATNIKNR3C2KDM2B
SCHEMBL990260 0.75 ERBB2 (0.55) MAPK14ERBB2MAPK8MAPK9CSNK1D
SCHEMBL991427 0.74 MAPK14 (0.50) MAPK14ERBB2MAPK8MAPK9CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863310-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2011-01-04 US disclosed
US-20080227839-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-09-18 US disclosed
EP-1720862-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-11-15 EP disclosed
WO-2005080380-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227839-A1 Kinase Inhibitors ABL1, MAP3K20, MAP3K19 MAPK14 341/4885ERBB2 44/4885MAPK8 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.